Company
About us
History
Leaderships
Team
EU grants
Requests for Proposal
Sustainability – ESG
Bussines strategy
Quality policy
Virtual Tour
Investors
Corporate documents
Shareholders and shares
Periodic reports
Current reports
Sustainability reports
Corporate governance at Mabion
Financial data
For Investors
Calendar
Science News
Resources
Monoclonal antibody
Breast Cancer Targeted Therapies and Immunotherapies
Antibody-drug conjugates
,
Biologics
,
Cancer
,
Monoclonal antibody
Monoclonal Antibody Production in Modern Biologics Manufacturing
GMP
,
Manufacturing
,
Monoclonal antibody
PD-1 Antibody Development Programs for Cancer Immunotherapy
Bispecific antibody
,
Cancer
,
Drug substance
,
Manufacturing
,
Monoclonal antibody
High-yield mAbs Manufacturing Platform Approach
Drug substance
,
Mabion
,
Manufacturing
,
Monoclonal antibody
Innovative Biologics Expected Approvals in 2026
Antibody-drug conjugates
,
Biologics
,
Bispecific antibody
,
Clinical trials
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
Monoclonal Antibody Prophylaxis for Infectious Diseases – Passive Immunization and Prevention
Monoclonal antibody
,
Vaccines
From Research to Release: Mapping Mabion’s Full Analytical Lifecycle for Monoclonal Antibodies
Analytics
,
Mabion
,
Monoclonal antibody
Antibodies Development Best Practices for CDMO Collaboration
Drug development
,
Manufacturing
,
Monoclonal antibody
Innovative Biologics – Expected Drug Approvals in 2025
Antibody-drug conjugates
,
Biologics
,
Bispecific antibody
,
Clinical trials
,
EMA
,
FDA
,
Monoclonal antibody
,
Vaccines
1
2
Next